<DOC>
	<DOCNO>NCT02713750</DOCNO>
	<brief_summary>This study create model reproductive health service HIV-positive female adolescent Asia .</brief_summary>
	<brief_title>RH Adolescents</brief_title>
	<detailed_description>For implementation risk reduction intervention , equally important provide specific knowledge continuous counsel different preventive option . A perfect preventive method , provide highly reliable dual protection unintended pregnancy HIV/STDs side effect completely accept , available . Many author consider effective way achieve dual protection simultaneous use two contraceptive method , one barrier method male female condom , highly effective contraceptive method , hormonal contraception ( HC ) , intrauterine device ( IUD ) sterilization . This call dual contraception . Therefore project focus specific reproductive service delivery group patient . As age group young , investigator use study reversible highly effective method contraception - HC , combine progestin , IUD - condom . For example , HC HIV-positive woman study extensively last two decade , yet still definitive answer regard key issue - HIV disease progression , genital tract HIV shed infectivity , pharmacokinetic ( PK ) interaction hormone ARVs , therefore possibility compromise contraceptive effect and/or ARV failure , last least , metabolic outcome . Data effect hormonal contraception HIV disease progression still inconclusive . Unfortunately limited number study field , small sample sizes case outside `` real life '' condition . There three substudies : 1 . Pharmacokinetic interaction sex steroid hormone protease inhibitor HIV-positive Thai female adolescent 2 . Assessment premenstrual syndrome HIV-positive adolescent 3 . Metabolic change HIV + female adolescent ART hormonal contraception</detailed_description>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Female 12 24 year age HIVpositive status HIVdisclosed screen visit Having first menstrual cycle ( menarche ) Sexually active Willing participate study sign informed consent form , include sign inform consent caretaker subject &lt; 18 year age Being pregnant time screen visit Mental physical condition may limit informed participation study Having active AIDS opportunistic infection Noneligible subject use hormonal contraception : Thrombosis history Family history thrombosis Hypertension ( combine oral contraceptive ) Hyperlipidemia ( toxicity grade &gt; 3 ) Diabetes mellitus vascular involvement Presence history liver hepatic disease Malignant disease genital organ breast Undiagnosed vaginal bleeding Lactation Hypersensitivity steroid hormone Eligible subject use intrauterine device : In case HAART , last CD4 count &gt; 200 cells/mm3 6 month prior screen If without HAART , last CD4 count &gt; 350 cells/mm3 6 month prior screen Normal cervical Pap smear last 6 months/in day IUD insertion Noneligible subject use intrauterine device : Having active infection vagina cervix Having pelvic inflammatory disease ( PID ) recent history PID Having bleed disorder take anticoagulant Having abnormality uterus Having uterine infection childbirth septic abortion Having uterine bleed unknown origin Having allergy copper</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Combined Oral Contraceptives</keyword>
	<keyword>Highly Active Antiretroviral Therapy</keyword>
	<keyword>Hormonal Contraception</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Intrauterine Device</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Sexually Transmitted Diseases</keyword>
	<keyword>Reproductive Health</keyword>
</DOC>